The diabetes drugs market, valued as a USD 20 billion market in 2010, is expected to grow at an exponential rate and become a USD 32 billion market by 2017, at a CAGR of about 7.5%.
Diabetes, often referred to by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body's cells do not respond properly to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia). Diabetes is a chronic metabolic disease wherein the body is either not able to produce insulin (type-1) or is not able to utilize the generated insulin (type-2). This elevated sugar level leads to various symptoms such as increased thirst, weight loss, increased appetite and frequent and sweet-smelling urination. If untreated, diabetes causes various acute and chronic life-threatening complications.
Global Diabetes Drugs Market- Market Dynamics
This report studies the current as well as the future scenario of the diabetes diagnostic devices and drugs market globally. The report details several driving and restraining factors for this market. Some of them are listed below.
Some of the factors driving the growth of this market are:
There are some restraining factors that the market faces. These include:
The market is segmented on the basis of diabetic drugs, devices, and geography. The diabetic drugs market is again segmented into categories, which are insulin derivatives and oral diabetic medication drugs. On the basis of geography, the market is segmented into North America, Europe, APAC and the Rest of the World.
Some of the key players in the market are:
Key Deliverables in the Study